Clinuvel Pharmaceuticals LimitedASX: CUV

First positive observations from Clinuvel`s vitiligo trial

· Issued by Clinuvel Pharmaceuticals Limited

Filed with ASX · · 6 pages · English

On 6ix: 6ix.com/news/first-positive-observations-from-clinuvels-vitiligo-trial

Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that early clinical observations from the company’s open label Phase II pilot trial (CUV102) of the novel drug SCENESSE® (afamelanotide) in patients with nonsegmental vitiligo (NSV) were presented at the European Academy of Dermatology and Venereology (EADV) meeting in Lisbon overnight. Two clinical investigato

Clinuvel Pharmaceuticals Limited on 6ix